An announcement from Urogen Pharma ( (URGN) ) is now available.
UroGen Pharma Ltd. announced the departure of CFO Don Kim, who will continue to provide consulting services until April 2025 and has a benefits package including his salary and bonus. Concurrently, Christopher Degnan has been appointed the new CFO, bringing experience from various pharmaceutical firms. Degnan’s compensation includes a $500,000 base salary, potential bonuses, and equity awards with a vesting schedule, along with severance benefits in certain termination scenarios.
See more data about URGN stock on TipRanks’ Stock Analysis page.
